SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders discuss potential U.S.-China trade deal impacts and the strength of big tech companies like Apple, with community members weighing in on bullish and bearish signals. Debate centers around whether recent market behavior is indicative of a healthy consolidation or a looming correction, with some expressing concerns about potential risks in AI and regional banks. News of potential interest rate cuts, rising treasury yields, and key economic data releases are adding to the conversation.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as the community discusses its recent price surge and potential for further gains, with some targeting prices such as $300 and beyond. Privacy narratives and comparisons to Bitcoin are circulating, while others speculate on market manipulation and future price corrections. Discussions also include the upcoming 9 year anniversary.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to community discussion around its low float, regained NASDAQ compliance, and a recently announced contract, drawing comparisons to other Hong Kong-based stocks that have experienced significant gains. Traders are also noting the high cost to borrow, speculating about a potential short squeeze. The company's expansion into EV infrastructure and AI-powered solutions is adding to the positive sentiment.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors discuss the potential of ivonescimab, particularly following trial data suggesting reduced cancer progression risk; the community is analyzing the drug's efficacy and overall survival benefits, while also considering potential regulatory hurdles and competition in the oncology market. Some traders point to insider buying as a bullish signal, while others express caution regarding the drug's performance in specific patient groups and the company's overall valuation. The conversation also includes speculation about potential partnerships and upcoming presentations of trial data.

SSgA Active Trust - Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The technology sector, represented by XLK, is seeing mixed signals with potential tariff implications and leadership shifts impacting market sentiment. Community discussions revolve around whether current levels can be sustained, and if a broader market pullback is on the horizon, especially given earnings results from major tech companies and conflicting reports regarding trade policies. Despite some analysts remaining bullish, concerns about the sector's future performance are being actively discussed.

Fuzzybear ($FUZZY) is a memecoin on the XRP Ledger (XRPL), created to honor the legacy of the well-known XRPL address ‘Fuzzybear,’ which famously placed a DEX order in 2014: 1 XRP for 1 BTC. The token embodies the spirit of decentralization and community-driven growth, focusing on fun, engagement, and organic expansion. With its unique narrative and strong community, Fuzzybear grows naturally as more supporters join the movement.

Fuzzybear

Fuzzybear ($FUZZY) is trending as community members highlight its connection to XRP and potential role within the XRP Ledger ecosystem, with some suggesting it could be the next big memecoin. Discussions also mention an upcoming event and the potential for exchange listings, fueling speculation and interest. Community members also note that David Schwartz, Ripple's CTO, recently joined a discussion about Fuzzybear on X.

Towns

$TOWNS is trending as community members actively discuss recent price movements and encourage others to join. Some users highlight potential for significant gains, while others speculate about exchange listings and future developments. The community references other trending tickers and possible connections to external entities, contributing to the heightened interest.

Alchemy Pay

Alchemy Pay is trending due to discussions around potential partnerships, developments in stablecoin integration, and speculation about future price movements. Community members are actively debating its utility, price predictions, and whether it will follow the performance of other cryptocurrencies. The focus seems to be on Alchemy Pay's role in facilitating fiat-to-crypto transactions and its potential for growth in the evolving digital payment landscape.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is garnering attention as community members discuss its potential, partnerships, and valuation relative to competitors like Progressive. Conversations revolve around whether the company can translate partnerships into substantial growth and if upcoming earnings will reflect this. Despite recent price declines, some investors remain optimistic, viewing it as an undervalued opportunity with long-term potential akin to early-stage Tesla or Hood.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics ($CORT) is trending due to positive Phase 3 ROSELLA trial results showing improved progression-free survival for patients with platinum-resistant ovarian cancer, sparking investor optimism. The community is discussing the potential for relacorilant to become a new standard of care and its impact on the company's growth. Broader interest may also stem from Corcept's pipeline and focus on endocrinologic, oncologic, metabolic and neurologic disorders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy TLRY Stock After Encouraging Q1 Results?

Tilray's return to profitability, stronger cash flow, and expanding global cannabis and beverage operations highlight its renewed growth story.

Should You Buy or Sell CURLF Stock Amid Renewed Legalization Hopes?

Curaleaf's shares have soared over 200% on renewed legalization optimism, but domestic weakness and profit hurdles cloud the outlook.

Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?

Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Implied Volatility Surging for Aurora Cannabis Stock Options

Investors need to pay close attention to ACB stock based on the movements in the options market lately.

Here's Why JAZZ Stock Is an Unconventional Cannabis Investment

Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.

Retail Expansion Positions High Tide for Long-Term Growth

HITI expands Canna Cabana to 203 stores, boosting market share and outpacing peers with 2.3X revenue per location.

Cannabis Stock VRNOF Soars 178% in a Month: Time to Buy, Sell or Hold?

Verano's stock has surged 178% in a month on reform hopes, but pricing pressure and stiff competition test its momentum.

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


President Donald Trump confirmed on Monday that he is looking at reclassifying marijuana and may announce his final decision in the next few weeks. "We're looking at reclassification, and we'll make a determination over the next few weeks," Trump told reporters during a press conference about cracking down on crime in Washington, D.C.His comments come after The Wall Street Journal (WSJ)&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">reported</a> last week that Trump may be interested in changing the drug’s classification. Marijuana-linked stocks like Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), Cronos Group (CRON), and Trulieve Cannabis (TCNNF) were already rallying in pre-market trade on the report.&nbsp;They continued to rally after Trump’s confirmation, with&nbsp;<a href="http://stocktwits.com/symbol/CGC">Canopy Growth’s</a> stock surging nearly 30% in midday trade.&nbsp;<a href="http://stocktwits.com/symbol/TLRY">Tilray’s stock</a> jumped 22%, followed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://tcnnf">Trulieve’s stock</a> gaining more than 18%. Aurora Cannabis’s stock climbed 12.5% on Monday.On Stocktwits, retail sentiment around Canopy Growth moved higher within ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter. Meanwhile, retail sentiment around Tilray Brands improved to ‘bullish’ from ‘bearish’ a day ago, and retail sentiment around Trulieve was moved higher within ‘extremely bullish’ territory.“Some people like it. Some people hate it. Some people hate the whole concept of marijuana, because if it’s bad for the children, it’s bad for people older than children,” the President said, noting that medical marijuana, specifically, may hold benefits.&nbsp;“I’ve heard great things to do with medical, and I’ve heard bad things having to do with just about everything else but medical,” he said.Reclassification of marijuana from a Schedule I drug to a Schedule III drug would ease restrictions, allow tax breaks, and expand medical research.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-declares-liberation-day-in-dc-pushes-takeover-of-city-police/chrHGOoRdee">Trump Declares ‘Liberation Day’ in DC, Pushes Takeover Of City Police</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions during a press conference in the James S. Brady Press Briefing Room of the White House August 11, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’ 

The President noted that there’s a difference of opinion on the benefits of marijuana, but added that he’s heard “great things” with respect to medical marijuana, specifically.

Equity

Retail sentiment picked up Sunday for Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Trulieve Cannabis (TCNNF) after reports that U.S. President Donald Trump may reclassify marijuana as a less dangerous drug.&nbsp;The Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">said</a> that at a $1 million-a-plate fundraiser at his New Jersey golf club earlier this month, Trump told guests he was interested in the change, signaling an effort the Biden administration had started but never completed.Reclassification to Schedule III would ease restrictions, allow tax breaks, and expand medical research. Trulieve CEO Kim Rivers reportedly urged Trump to pursue the shift and expand research. Trump flagged the idea to staff. Other guests included Pfizer’s CEO, cryptocurrency executives, and political advisers.Cannabis companies have contributed millions to Trump’s political groups, hired lobbyists close to him, and backed American Rights and Reform PAC, which gave $1 million to Trump’s PAC and commissioned polling from Trump pollster Tony Fabrizio showing Republican and independent voter support.The PAC also paid $300,000 to Trump adviser Alex Bruesewitz for social media and advertising work.Bruesewitz said, “This is not calling for decriminalization or legalization but simply knocking it down a few notches on the criminal scale.”Trump said last year he would vote for legalization in Florida after meeting with Trulieve and lobbyist Brian Ballard. Senior officials said he does not personally support marijuana but is interested in “80-20 cultural issues” with broad backing and has referenced friends who used medical marijuana.Opposition groups include Smart Approaches to Marijuana, which has run ads on Fox programs, and the Community Anti-Drug Coalitions of America, which urged members to contact the White House.White House spokeswoman Abigail Jackson said, “All policy and legal requirements and implications are being considered. The only interest guiding the president’s policy decisions is what is in the best interest of the American people.”On Stocktwits, retail sentiment was “extremely bullish” with “high” message volume for ACB, CGC, and TCNNF, while CRON was “bullish” with “high” message volume.One user noted that cannabis company stocks jumped between 30% and 40% after multiple reports in April 2024 that marijuana would be reclassified to a less dangerous drug schedule.<stembedurl>https://stocktwits.com/Icarus81/message/624511957</stembedurl>Another user pointed out that the last time there was similar regulatory talk, ACB rose sharply to more than $8 a share, and said it should be “an interesting week to say the least.”<stembedurl>https://stocktwits.com/LionsFan/message/624533180</stembedurl>So far this year, ACB is up 5.4%, CGC is down 54.4%, CRON is up 13.9% and TCNNF is up 10.5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, ACB is up 5.4%, CGC is down 54.4%, CRON is up 13.9% and TCNNF is up 10.5%. (Photo credit: Getty Images)

Retail Bulls Pile Into Cannabis Stocks On Reports Trump May Reclassify Marijuana; Traders Eye Aurora Rally

Cannabis firms have spent millions lobbying Trump to shift marijuana to Schedule III, easing restrictions and enabling tax breaks.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ACB
Aurora Cannabis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACB News

ACBAurora Cannabis Inc